Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPASALT
2016-002961-79Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Started Feb 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2016-002961-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002961-79.